Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
Summary The Strategy outperformed for the second quarter in a row, thanks in large part to positioning adjustments made over the last year in preparation for these extreme macro headwinds. We enhanced a focus on sturdy, secular growth businesses with three new additions to the portfol...
Summary International growth stocks held up better than value, snapping a two-quarter losing streak, as global recession fears weighed more heavily on companies tied to the broader economy. The Strategy outperformed for the second quarter in a row, thanks in large part to position...
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said on Sept. 26 that Ezharmia was approved in Japan to treat patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL), a rare type of blood cancer. Ezharmia (valemetostat tosilate) is the first ...
Gilead Sciences ( NASDAQ: GILD ) shares reached the highest level since February on Monday in reaction to its announcement that antibody-drug conjugate Trodelvy significantly improved overall survival in a Phase 3 trial involving certain patients with HR+/ HER2- metastatic bre...
AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo's ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) Enhertu delayed disease progression, meeting the main goal of a phase 3 trial in patients with a type of breast cancer. The study, dubbed DESTINY-Breast02, evaluated Enhertu (t...
Merck & Co.'s ( NYSE: MRK ) potential $40 billion acquisition of Seagen ( NASDAQ: SGEN ) is likely to be back in focus after the cancer drug maker had unfavorable outcome in its arbitration with the Japanese pharma Daiichi Sankyo ( OTCPK:DSKYF ). While ...
The shares of cancer biotech Seagen Inc. ( NASDAQ: SGEN ) dropped after the company announced an unfavorable outcome to its 2008 collaboration agreement with Japanese pharma company Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) over the use of antibody-drug conjugate ...
The FDA has issued premarket approval for Thermo Fisher Scientific's ( NYSE: TMO ) Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients with HER2 activating mutations in their non-small cell lung cancer who might be eligible for antibody-drug conjugate En...
Health Canada has approved Lynparza (olaparib) as an adjuvant treatment for germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer. The approval is for patients who have been treated with neoadjuvant or adjuva...
The U.S. FDA has granted an additional approval to AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo's ( OTCPK:DSNKY ) ( OTCPK:DSKYF ) Enhertu (trastuzumab deruxtecan) for HER2-low breast cancer . The approval is the first for a targeted therapy for the breast can...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...